ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
PR Newswire —
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it...